Cable Hill Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Cable Hill Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$21K	–	779
2018 Q3	$21K	Buy	1,000 +500	+100%	+$7.87K	0.01%	304
2018 Q2	$8K	Buy	+500	New	+$8.91K	﹤0.01%	521
2018 Q1	–	Sell	-400	Closed	-$12K	–	882
2017 Q4	$12K	Buy	+400	New	+$12.8K	0.01%	520
2016 Q3	–	Sell	-138	Closed	-$4.68K	–	894
2016 Q2	$5K	Hold	138	–	–	﹤0.01%	490
2016 Q1	$4K	Sell	138 -6	-4%	-$131	﹤0.01%	497
2015 Q4	$6K	Sell	144 -5	-3%	-$176	﹤0.01%	428
2015 Q3	$5K	Buy	+149	New	+$6.2K	﹤0.01%	485

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cable Hill Partners's ACAD Position: Q4 2018 in Review

Cable Hill Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 1,000 shares — an estimated $21K sold.

Cable Hill Partners first reported a position in ACAD in Q3 2015 and held it in 7 quarters. The position peaked at $21K in Q3 2018. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

Cable Hill Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Cable Hill Partners sold 1,000 Acadia Pharmaceuticals shares in Q4 2018, an estimated $21K.
Cable Hill Partners first reported a position in Acadia Pharmaceuticals in Q3 2015 and held it in 7 quarters.
Cable Hill Partners's Acadia Pharmaceuticals position peaked at $21K in Q3 2018.
186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on Cable Hill Partners's 13F filing for Q4 2018, filed 12 Feb 2019.